A Randomized Non-Comparative Phase 2 Study of Anti-Programmed Cell Death-Ligand 1 Atezolizumab or Chemotherapy as Second-Line Therapy in Patients with Small Cell Lung Cancer: Results from the IFCT 1603 Trial

  • Etude concernée: IFCT-1603
  • Auteurs / Authors: Pujol JL, Greillier L, Audigier-Valette C, Moro-Sibilot D, Uwer L, Hureaux J, Guisier F, Carmier D, Madelaine J, Otto J, Gounant V, Merle P, Mourlanette P, Molinier O, Renault A, Rabeau A, Antoine M, Denis MG, Bommart S, Langlais A, Morin F, Souquet PJ
  • Journal / Conference: Journal of Thoracic Oncology
  • Année / Year: 2019
  • PMID: 30664989
  • Lien vers la publication: https://www.ncbi.nlm.nih.gov/pubmed/30664989